Targeting Lonidamine to Mitochondria Mitigates Lung Tumorigenesis and Brain Metastasis
A mitochondria-targeted lonidamine derivative shows enhanced potency against lung cancer, offering a promising new therapeutic avenue.
Get a Quote & SampleProduct Core Value
Lonidamine Powder
This research explores the development of Mito-LND, a mitochondria-targeted derivative of lonidamine (LND), designed to overcome the limitations of LND's poor efficacy and selectivity. By specifically targeting mitochondria, Mito-LND demonstrates significantly enhanced potency in inhibiting cancer cell growth and metastasis.
- Mito-LND significantly enhances lonidamine's potency by targeting cancer cell mitochondria.
- The drug functions by inhibiting oxidative phosphorylation, crucial for cancer cell energy production.
- Mito-LND effectively induces autophagic cell death, a key mechanism in cancer treatment.
- Studies show that Mito-LND mitigates lung tumor growth and brain metastasis in preclinical models.
Key Advantages
Enhanced Potency
Mito-LND exhibits significantly higher potency compared to the original lonidamine, offering a more effective approach for cancer therapy using mitochondria targeting.
Reduced Toxicity
Preclinical studies indicate that Mito-LND has minimal toxicity even at high doses, making it a safer option for patients seeking lung cancer treatment.
Targeted Action
The mitochondria-specific delivery of Mito-LND ensures that the drug primarily acts on cancer cells, improving treatment outcomes for lung cancer brain metastasis.
Key Applications
Oncology Research
Investigating novel therapeutic strategies for various cancers, particularly focusing on mitochondria targeting in cancer therapy.
Lung Cancer Treatment
Developing advanced treatments for lung cancer, aiming to improve patient survival and reduce recurrence through innovative drug delivery methods like Mito-LND lung cancer treatment.
Metastasis Inhibition
Focusing on strategies to prevent and treat cancer metastasis, especially lung cancer brain metastasis, by targeting the underlying cellular mechanisms.
Drug Development
Advancing the field of targeted drug delivery, with a specific interest in lonidamine toxicity and how mitochondria-targeted delivery can overcome it.